

*Sub
C₁ cont'd*
(i) contacting a test compound with the *ycf 24* gene product, and

(ii) determining whether the test compound inhibits the activity of or binds to the product, any such binding or inhibition being indicative that the compound inhibits the growth of the organism.

13. (new) The method according to claim 12 in which the organism is a malaria parasite.

a
14. (new) A method of identifying a compound that inhibits the growth of an organism comprising the *ycf 24* gene, the method comprising

(i) contacting a test compound with a test construct comprising a *ycf 24* promoter operably linked to a coding sequence, and

(ii) determining whether the test compound inhibits expression driven by the promoter, any such inhibition being indicative that the compound inhibits the growth of the organism.

15. (new) The method according to claim 14 in which the organism is a malaria parasite.

16. (new) A pharmaceutical composition comprising an inhibitor of *ycf 24* gene product expression and/or activity and a pharmaceutically acceptable carrier or diluent.

17. (new) The pharmaceutical composition according to claim 16 wherein the inhibitor is an inhibitor of the growth of a malaria parasite.

18. (new) A method of preventing or treating infection by an organism comprising the *ycf 24* gene in a patient, said method comprising administering to the patient an inhibitor of *ycf 24* gene product expression and/or activity.

19. (new) The method according to claim 18 in which the organism is a malaria parasite.--

REMARKS

The above amendments are made to place the claims in a more traditional format. Claims 12-19 are pending.